-
-
[1] Elser C, Sweet J, Cheran SK, et al. A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens[J]. Can Urol Assoc J, 2012, 6(1):E27-31. [2] Siefker-Radtke A. Urachal adenocarcinoma: a clinician’s guide for treatment[J]. Semin Oncol, 2012, 39:619-624. doi: 10.1053/j.seminoncol.2012.08.011 [3] Kume H, Tomita K, Takahashi S, et al. Irinotecan as a new agent for urachal cancer[J]. Urol Int, 2006, 76:281-282. doi: 10.1159/000091635 [4] Riva G, Mian C, Luchini C, et al. Urachal carcinoma: from gross specimen to morphologic, immunohistochemical, and molecular analysis[J]. Virchows Arch, 2019, 474:13-20. doi: 10.1007/s00428-018-2467-1 [5] Testa I, Verzoni E, Grassi P, et al. Response to targeted therapy in urachal adenocarcinoma[J]. Rare Tumors, 2014, 6(4):5529. [6] Ma CX, Janetka JW, Piwnica-Worms H. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics[J]. Trends Mol Med, 2011,17(2):88-96. [7] Reis H, Herold T, Ting S, et al. HER2 expression and markers of phosphoinositide-3-kinase pathway activation define a favorable subgroup of metastatic pulmonary adenocarcinomas[J]. Lung Cancer, 2015, 88:34-41. [8] Moujaess E, Haddad FG. The emerging use of immune check-point blockade in the adjuvant setting for solid tumors: a review[J]. J Immuno Ther Cancer, 2019, 11(16):1409-1422. [9] Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phaseⅡKEYNOTE-158 study[J]. J Clin Oncol, 2019, 38(1):1-10. -
下载:
点击查看大图
图(6)
计量
- 文章访问数: 246
- HTML全文浏览量: 179
- PDF下载量: 46
- 被引次数: 0
